{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:45Z","timestamp":1792098585244,"version":"4.4.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T00:00:00Z","timestamp":1581292800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100012681","name":"Universit\u00e4tsklinikum K\u00f6ln","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100012681","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Z Rheumatol"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:sec><jats:title>Hintergrund<\/jats:title><jats:p>Das Raynaud-Ph\u00e4nomen und die damit h\u00e4ufig einhergehenden digitalen Ulzerationen stellen f\u00fcr Patienten mit systemischer Sklerose (Sklerodermie [SSc]) ein fr\u00fches und sehr belastendes Symptom mit bedeutenden Einschr\u00e4nkungen der Arbeitsf\u00e4higkeit und Lebensqualit\u00e4t dar. Der Einsatz vasoaktiver Medikamente (insbesondere intraven\u00f6ser Prostazyklinderivate) soll helfen, das Risiko hypoxischer Gewebesch\u00e4den bis hin zum Verlust der Finger zu reduzieren.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methoden<\/jats:title><jats:p>Um Aufschluss \u00fcber die aktuelle Versorgung von Patienten mit Prostazyklinderivaten im klinischen Alltag in Deutschland zu erhalten, f\u00fchrten wir eine Umfrage unter den im Deutschen Netzwerk f\u00fcr systemische Sklerodermie (DNSS) zusammengeschlossenen Kliniken durch. Zus\u00e4tzlich erfolgte eine separate Patientenbefragung \u00fcber die Sklerodermie Selbsthilfe e.\u202fV., die sich nur auf die Symptome \u201eRaynaud-Ph\u00e4nomen\u201c und \u201eDigitale Ulzera\u201c und den Einsatz intraven\u00f6ser Prostazyklinderivate bezog.<\/jats:p><\/jats:sec><jats:sec><jats:title>Ergebnisse<\/jats:title><jats:p>Von den befragten 433 Patienten gaben 56\u202f% an, dass sie bereits aufgrund ihrer Erkrankung und Symptome mit Prostazyklinderivaten behandelt wurden. Insgesamt 61\u202f% erhielten die Therapie aufgrund starker Raynaud-Symptomatik und 39\u202f% aufgrund digitaler Ulzerationen. Die meisten Befragten erfuhren durch die Therapie nicht nur eine Verbesserung des Raynaud-Ph\u00e4nomens und der digitalen Ulzera, sondern auch eine wesentliche Verbesserung von Einschr\u00e4nkungen im Alltag. Sie gaben zudem an, wesentlich weniger fremde Hilfe in Anspruch genommen sowie wesentlich weniger Fehlzeiten bei der Arbeit gehabt zu haben.<\/jats:p><\/jats:sec><jats:sec><jats:title>Schlussfolgerung<\/jats:title><jats:p>Die Patienten empfanden durchweg einen positiven Effekt der Therapie mit Prostazyklinderivaten auf das Raynaud-Ph\u00e4nomen, ihre digitalen Ulzerationen, Schmerzen und Alltagseinschr\u00e4nkung und f\u00fchlten sich durch die station\u00e4re Therapie gut und sicher betreut. Diese positiven Effekte in der Patientenwahrnehmung sind eine eindr\u00fcckliche St\u00fctze und best\u00e4tigen nachdr\u00fccklich die auf europ\u00e4ischer und internationaler Ebene erarbeiteten Therapieempfehlungen.<\/jats:p><\/jats:sec>","DOI":"10.1007\/s00393-019-00743-9","type":"journal-article","created":{"date-parts":[[2020,2,10]],"date-time":"2020-02-10T11:02:51Z","timestamp":1581332571000},"page":"1057-1066","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Versorgungsrealit\u00e4t der station\u00e4ren vasoaktiven Therapie mit Prostazyklinderivaten bei Patienten mit akralen Durchblutungsst\u00f6rungen bei systemischer Sklerose in Deutschland","Reality of inpatient vasoactive treatment with prostacyclin derivatives in patients with acral circulation disorders due to systemic sclerosis in Germany"],"prefix":"10.1007","volume":"79","author":[{"given":"A.","family":"Juche","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Siegert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U.","family":"Mueller-Ladner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Riemekasten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"G\u00fcnther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Henes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. E.","family":"Voll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ehrchen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schmalzing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Susok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Schmeiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sunderkoetter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Distler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Worm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Kreuter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O. N.","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. P.","family":"Sch\u00f6n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Korsten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Zeidler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Krieg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Hunzelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Moinzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,10]]},"reference":[{"key":"743_CR1","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1093\/rheumatology\/keq097","volume":"49","author":"L Amanzi","year":"2010","unstructured":"Amanzi\u00a0L, Braschi\u00a0F, Fiori\u00a0G et al (2010) Digital ulcers in scleroderma: staging, characteristics and sub-setting through observation of 1614 digital lesions. Rheumatology 49:1374\u20131382","journal-title":"Rheumatology"},{"key":"743_CR2","unstructured":"Anonymous (Stand: 05.2013) Fachinformation Ilomedin 20\u202fug\/1\u202fml. Zulassungsnummer 424240000 Bayer Vital GmbH."},{"key":"743_CR3","first-page":"137","volume":"47","author":"S Bartolone","year":"1999","unstructured":"Bartolone\u00a0S, Trifiletti\u00a0A, De Nuzzo\u00a0G et\u00a0al (1999) Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud\u2019s phenomenon. Minerva Cardioangiol 47:137\u2013143","journal-title":"Minerva Cardioangiol"},{"key":"743_CR4","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","volume":"390","author":"CP Denton","year":"2017","unstructured":"Denton\u00a0CP, Khanna\u00a0D (2017) Systemic sclerosis. Lancet 390:1685\u20131699","journal-title":"Lancet"},{"key":"743_CR5","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1136\/annrheumdis-2014-207001","volume":"75","author":"E Hachulla","year":"2016","unstructured":"Hachulla\u00a0E, Hatron\u00a0PY, Carpentier\u00a0P et al (2016) Efficacy of sildenafil on ischaemic digital ulcer healing in systemic sclerosis: the placebo-controlled SEDUCE study. Ann Rheum Dis 75:1009\u20131015","journal-title":"Ann Rheum Dis"},{"key":"743_CR6","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1111\/bjd.14367","volume":"174","author":"N Hunzelmann","year":"2016","unstructured":"Hunzelmann\u00a0N, Riemekasten\u00a0G, Becker\u00a0MO et al (2016) The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase\u20111 antibodies. Br J Dermatol 174:1384\u20131387","journal-title":"Br J Dermatol"},{"key":"743_CR7","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.semarthrit.2018.03.019","volume":"48","author":"F Ingegnoli","year":"2019","unstructured":"Ingegnoli\u00a0F, Schioppo\u00a0T, Allanore\u00a0Y et\u00a0al (2019) Practical suggestions on intravenous iloprost in Raynaud\u2019s phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus. Semin Arthritis Rheum 48:686\u2013693","journal-title":"Semin Arthritis Rheum"},{"key":"743_CR8","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","volume":"76","author":"O Kowal-Bielecka","year":"2017","unstructured":"Kowal-Bielecka\u00a0O, Fransen\u00a0J, Avouac\u00a0J et al (2017) Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis 76:1327\u20131339","journal-title":"Ann Rheum Dis"},{"key":"743_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0755-4982(06)74645-0","volume":"35","author":"D Launay","year":"2006","unstructured":"Launay\u00a0D, Diot\u00a0E, Pasquier\u00a0E et\u00a0al (2006) Bosentan for treatment of active digital ulcers in patients with systemic sclerosis. Presse Med 35:587\u2013592","journal-title":"Presse Med"},{"key":"743_CR10","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1024\/0301-1526\/a000526","volume":"45","author":"B Linnemann","year":"2016","unstructured":"Linnemann\u00a0B, Erbe\u00a0M (2016) Raynaud\u2019s phenomenon and digital ischaemia\u2014pharmacologic approach and alternative treatment options. Vasa 45:201\u2013212","journal-title":"Vasa"},{"key":"743_CR11","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1136\/ard.2010.130658","volume":"70","author":"M Matucci-Cerinic","year":"2011","unstructured":"Matucci-Cerinic\u00a0M, Denton\u00a0CP, Furst\u00a0DE et al (2011) Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS\u20112 randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 70:32\u201338","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 5","key":"743_CR12","doi-asserted-by":"publisher","first-page":"v46","DOI":"10.1093\/rheumatology\/ken310","volume":"47","author":"M Matucci-Cerinic","year":"2008","unstructured":"Matucci-Cerinic\u00a0M, Seibold\u00a0JR (2008) Digital ulcers and outcomes assessment in scleroderma. Rheumatology 47(Suppl 5):v46\u2013v47","journal-title":"Rheumatology"},{"key":"743_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1136\/annrheumdis-2014-205897","volume":"75","author":"C Mihai","year":"2016","unstructured":"Mihai\u00a0C, Landewe\u00a0R, Van Der Heijde\u00a0D et\u00a0al (2016) Digital ulcers predict a\u00a0worse disease course in patients with systemic sclerosis. Ann Rheum Dis 75:681\u2013686","journal-title":"Ann Rheum Dis"},{"key":"743_CR14","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.44.11.754","volume":"44","author":"JS Mohrland","year":"1985","unstructured":"Mohrland\u00a0JS, Porter\u00a0JM, Smith\u00a0EA et al (1985) A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud\u2019s syndrome. Ann Rheum Dis 44:754\u2013760","journal-title":"Ann Rheum Dis"},{"key":"743_CR15","doi-asserted-by":"publisher","first-page":"66","DOI":"10.3899\/jrheum.150382","volume":"43","author":"P Moinzadeh","year":"2016","unstructured":"Moinzadeh\u00a0P, Riemekasten\u00a0G, Siegert\u00a0E et al (2016) Vasoactive therapy in systemic sclerosis: real-life therapeutic practice in more than 3000 patients. J\u00a0Rheumatol 43:66\u201374","journal-title":"J Rheumatol"},{"key":"743_CR16","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","volume":"19","author":"S Negrini","year":"2019","unstructured":"Negrini\u00a0S, Magnani\u00a0O, Matucci-Cerinic\u00a0M et al (2019) Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med 19:357\u2013366","journal-title":"Clin Exp Med"},{"key":"743_CR17","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000953","author":"J Pope","year":"2000","unstructured":"Pope\u00a0J, Fenlon\u00a0D, Thompson\u00a0A et\u00a0al (2000) Iloprost and cisaprost for Raynaud\u2019s phenomenon in progressive systemic sclerosis. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD000953","journal-title":"Cochrane Database Syst Rev"},{"key":"743_CR18","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1055\/s-0031-1298798","volume":"137","author":"G Riemekasten","year":"2012","unstructured":"Riemekasten\u00a0G, Hoffmann\u00a0U, Sunderkotter\u00a0C et\u00a0al (2012) Management of digital ulcers in patients with systemic sclerosis. Dtsch Med Wochenschr 137:34\u201340","journal-title":"Dtsch Med Wochenschr"},{"key":"743_CR19","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1093\/rheumatology\/key113","volume":"57","author":"T Schioppo","year":"2018","unstructured":"Schioppo\u00a0T, Orenti\u00a0A, Boracchi\u00a0P et al (2018) Acute and chronic effects of two different intravenous iloprost regimens in systemic sclerosis: a\u00a0pragmatic non-randomized trial. Rheumatology 57:1408\u20131416","journal-title":"Rheumatology"},{"key":"743_CR20","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1111\/j.1365-2133.2008.09004.x","volume":"160","author":"C Sunderkotter","year":"2009","unstructured":"Sunderkotter\u00a0C, Herrgott\u00a0I, Bruckner\u00a0C et\u00a0al (2009) Comparison of patients with and without digital ulcers in systemic sclerosis: detection of possible risk factors. Br J Dermatol 160:835\u2013843","journal-title":"Br J Dermatol"},{"key":"743_CR21","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1002\/acr.22018","volume":"65","author":"T Tingey","year":"2013","unstructured":"Tingey\u00a0T, Shu\u00a0J, Smuczek\u00a0J et al (2013) Meta-analysis of healing and prevention of digital ulcers in systemic sclerosis. Arthritis Care Res 65:1460\u20131471","journal-title":"Arthritis Care Res"},{"key":"743_CR22","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1111\/j.1610-0387.2010.07564.x","volume":"9","author":"J Wohlrab","year":"2011","unstructured":"Wohlrab\u00a0J, Schanz\u00a0S, Ulrich\u00a0J (2011) Iloprost in dermatology. J\u00a0Dtsch Dermatol Ges 9:56\u201363","journal-title":"J Dtsch Dermatol Ges"}],"container-title":["Zeitschrift f\u00fcr Rheumatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00393-019-00743-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00393-019-00743-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T10:50:56Z","timestamp":1722423056000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00393-019-00743-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,10]]},"references-count":22,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["743"],"URL":"https:\/\/doi.org\/10.1007\/s00393-019-00743-9","relation":{},"ISSN":["0340-1855","1435-1250"],"issn-type":[{"value":"0340-1855","type":"print"},{"value":"1435-1250","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,10]]},"assertion":[{"value":"10 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"A.\u00a0Juche, E.\u00a0Siegert, U.\u00a0Mueller-Ladner, G.\u00a0Riemekasten, C.\u00a0G\u00fcnther, I.\u00a0K\u00f6tter, J.\u00a0Henes, N.\u00a0Blank, R.E.\u00a0Voll, J.\u00a0Ehrchen, M.\u00a0Schmalzing, L.\u00a0Susok, T.\u00a0Schmeiser, C.\u00a0Sunderkoetter, J.\u00a0Distler, M.\u00a0Worm, A.\u00a0Kreuter, O.N.\u00a0Horv\u00e1th, M.P.\u00a0Sch\u00f6n, P.\u00a0Korsten, G.\u00a0Zeidler, C.\u00a0Pfeiffer, T.\u00a0Krieg, N.\u00a0Hunzelmann und P.\u00a0Moinzadeh geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Alle beschriebenen Untersuchungen am Menschen oder an menschlichem Gewebe wurden mit Zustimmung der zust\u00e4ndigen Ethikkommission, im Einklang mit nationalem Recht sowie gem\u00e4\u00df der Deklaration von Helsinki von 1975 (in der aktuellen, \u00fcberarbeiteten Fassung) durchgef\u00fchrt. Von allen beteiligten Patienten liegt eine Einverst\u00e4ndniserkl\u00e4rung vor.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}